First Business Financial Services Inc. Takes $343,000 Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

First Business Financial Services Inc. bought a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 20,000 shares of the biotechnology company's stock, valued at approximately $343,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of ADMA Biologics by 13.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock valued at $13,171,000 after purchasing an additional 80,400 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of ADMA Biologics during the 3rd quarter worth about $61,858,000. EWG Elevate Inc. acquired a new position in ADMA Biologics in the 4th quarter valued at about $480,000. Citigroup Inc. raised its holdings in ADMA Biologics by 251.7% in the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock valued at $7,741,000 after acquiring an additional 277,138 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after acquiring an additional 2,613,482 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Price Performance

NASDAQ ADMA traded down $0.77 on Thursday, hitting $16.91. 3,024,933 shares of the company's stock were exchanged, compared to its average volume of 3,342,201. ADMA Biologics, Inc. has a 52 week low of $5.88 and a 52 week high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a 50-day moving average of $16.69 and a 200-day moving average of $17.97. The stock has a market cap of $4.00 billion, a price-to-earnings ratio of 60.39 and a beta of 0.75.

Analyst Ratings Changes

ADMA has been the topic of several research reports. Raymond James upped their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research report on Friday, November 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday. Finally, HC Wainwright lifted their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.